An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Cancer
- Focus Therapeutic Use
- Acronyms CheckMate 627
- Sponsors Bristol-Myers Squibb
- 18 Jan 2018 Planned number of patients changed from 150 to 250.
- 29 Mar 2017 Planned End Date changed from 1 Jan 2018 to 4 Jan 2019.
- 06 Oct 2016 Status changed from not yet recruiting to recruiting.